HTG Molecular Diagnostics Inc (NASDAQ:HTGM) shares fell 1.2% during trading on Thursday . The company traded as low as $2.31 and last traded at $2.44, with a volume of 96,773 shares changing hands. The stock had previously closed at $2.47.

A number of brokerages have commented on HTGM. Zacks Investment Research lowered HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Canaccord Genuity reissued a “buy” rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a report on Friday, May 13th.

The company’s market cap is $17.20 million. The stock has a 50 day moving average of $2.49 and a 200-day moving average of $2.71.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.03. On average, equities research analysts anticipate that HTG Molecular Diagnostics Inc will post ($3.82) earnings per share for the current year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.